Cargando…

Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India

Background: Infection with HIV-2, a retrovirus that is closely related to HIV-1, is characterized by slower disease progression and transmission, longer latency period and low or undetectable viremia. Host immunity, including production of potent neutralizing antibodies, may be one of the possible c...

Descripción completa

Detalles Bibliográficos
Autores principales: Vidyavijayan, K. K., Cheedarala, Narayanaiah, Babu, Hemalatha, Precilla, Lucia K., Sathyamurthi, Pattabiraman, Chandrasekaran, Padmapriyadarsini, Murugavel, Kailapuri G., Swaminathan, Soumya, Tripathy, Srikanth P., Hanna, Luke Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304510/
https://www.ncbi.nlm.nih.gov/pubmed/30619250
http://dx.doi.org/10.3389/fimmu.2018.02841
_version_ 1783382376754184192
author Vidyavijayan, K. K.
Cheedarala, Narayanaiah
Babu, Hemalatha
Precilla, Lucia K.
Sathyamurthi, Pattabiraman
Chandrasekaran, Padmapriyadarsini
Murugavel, Kailapuri G.
Swaminathan, Soumya
Tripathy, Srikanth P.
Hanna, Luke Elizabeth
author_facet Vidyavijayan, K. K.
Cheedarala, Narayanaiah
Babu, Hemalatha
Precilla, Lucia K.
Sathyamurthi, Pattabiraman
Chandrasekaran, Padmapriyadarsini
Murugavel, Kailapuri G.
Swaminathan, Soumya
Tripathy, Srikanth P.
Hanna, Luke Elizabeth
author_sort Vidyavijayan, K. K.
collection PubMed
description Background: Infection with HIV-2, a retrovirus that is closely related to HIV-1, is characterized by slower disease progression and transmission, longer latency period and low or undetectable viremia. Host immunity, including production of potent neutralizing antibodies, may be one of the possible contributors to the distinction between the two infections. In an attempt to understand whether HIV-2 infection results in production of neutralizing antibodies and to characterize the nature of the neutralization response we screened plasma of 37 HIV-2 infected individuals for the presence of broadly neutralizing antibodies. Materials and Methods: Thirty seven asymptomatic, ART-naïve, HIV-2 infected individuals were recruited for the study. Plasma obtained from these individuals were screened for the presence of broadly cross reactive neutralizing antibodies (BCNabs) using the standard neutralization screening protocol with a panel of HIV-1 and HIV-2 pseudoviruses. Plasma exhibiting broad neutralization activity were assessed for their potency employing a titration assay. Further, an attempt was made to characterize the neutralization specificity of the plasma exhibiting broad and potent neutralization activity. Result: While majority of the samples tested were capable of neutralizing HIV-2 pseudoviruses with high to moderate potency, one unique sample demonstrated broad cross clade and cross type neutralization with ability to strongly neutralize the vast majority of both HIV-1 and HIV-2 viruses tested (19/20). Preliminary analyses indicate the possible presence of antibodies with multiple glycan epitope binding specificities. Conclusion: The study identified a unique HIV-2 sample with exceptional ability to neutralize HIV-2 viruses and cross-neutralize HIV-1 viruses with great breadth and potency. This sample holds promise for isolation of novel monoclonal antibodies that may exploited as potential therapeutic tools for HIV infection.
format Online
Article
Text
id pubmed-6304510
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63045102019-01-07 Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India Vidyavijayan, K. K. Cheedarala, Narayanaiah Babu, Hemalatha Precilla, Lucia K. Sathyamurthi, Pattabiraman Chandrasekaran, Padmapriyadarsini Murugavel, Kailapuri G. Swaminathan, Soumya Tripathy, Srikanth P. Hanna, Luke Elizabeth Front Immunol Immunology Background: Infection with HIV-2, a retrovirus that is closely related to HIV-1, is characterized by slower disease progression and transmission, longer latency period and low or undetectable viremia. Host immunity, including production of potent neutralizing antibodies, may be one of the possible contributors to the distinction between the two infections. In an attempt to understand whether HIV-2 infection results in production of neutralizing antibodies and to characterize the nature of the neutralization response we screened plasma of 37 HIV-2 infected individuals for the presence of broadly neutralizing antibodies. Materials and Methods: Thirty seven asymptomatic, ART-naïve, HIV-2 infected individuals were recruited for the study. Plasma obtained from these individuals were screened for the presence of broadly cross reactive neutralizing antibodies (BCNabs) using the standard neutralization screening protocol with a panel of HIV-1 and HIV-2 pseudoviruses. Plasma exhibiting broad neutralization activity were assessed for their potency employing a titration assay. Further, an attempt was made to characterize the neutralization specificity of the plasma exhibiting broad and potent neutralization activity. Result: While majority of the samples tested were capable of neutralizing HIV-2 pseudoviruses with high to moderate potency, one unique sample demonstrated broad cross clade and cross type neutralization with ability to strongly neutralize the vast majority of both HIV-1 and HIV-2 viruses tested (19/20). Preliminary analyses indicate the possible presence of antibodies with multiple glycan epitope binding specificities. Conclusion: The study identified a unique HIV-2 sample with exceptional ability to neutralize HIV-2 viruses and cross-neutralize HIV-1 viruses with great breadth and potency. This sample holds promise for isolation of novel monoclonal antibodies that may exploited as potential therapeutic tools for HIV infection. Frontiers Media S.A. 2018-12-17 /pmc/articles/PMC6304510/ /pubmed/30619250 http://dx.doi.org/10.3389/fimmu.2018.02841 Text en Copyright © 2018 Vidyavijayan, Cheedarala, Babu, Precilla, Sathyamurthi, Chandrasekaran, Murugavel, Swaminathan, Tripathy and Hanna. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Vidyavijayan, K. K.
Cheedarala, Narayanaiah
Babu, Hemalatha
Precilla, Lucia K.
Sathyamurthi, Pattabiraman
Chandrasekaran, Padmapriyadarsini
Murugavel, Kailapuri G.
Swaminathan, Soumya
Tripathy, Srikanth P.
Hanna, Luke Elizabeth
Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India
title Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India
title_full Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India
title_fullStr Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India
title_full_unstemmed Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India
title_short Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India
title_sort cross type neutralizing antibodies detected in a unique hiv-2 infected individual from india
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304510/
https://www.ncbi.nlm.nih.gov/pubmed/30619250
http://dx.doi.org/10.3389/fimmu.2018.02841
work_keys_str_mv AT vidyavijayankk crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT cheedaralanarayanaiah crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT babuhemalatha crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT precillaluciak crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT sathyamurthipattabiraman crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT chandrasekaranpadmapriyadarsini crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT murugavelkailapurig crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT swaminathansoumya crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT tripathysrikanthp crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia
AT hannalukeelizabeth crosstypeneutralizingantibodiesdetectedinauniquehiv2infectedindividualfromindia